Levetiracetam Stragen

Levetiracetam, the active ingredient in Levetiracetam Stragen, is an anticonvulsant presented as an intravenous solution for intravenous use. It is indicated for the management of epilepsy, including partial seizures and generalized tonic‑clonic seizures, in patients who require parenteral therapy.

GNH USA supplies Levetiracetam Stragen as a licensed, EU‑origin, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European regulatory standards and is distributed under strict quality controls.

Levetiracetam is an anticonvulsant used in the treatment of epilepsy and related seizure disorders.

- Partial seizures: reduces the frequency of focal onset seizures. - Generalized tonic‑clonic seizures: helps control convulsive seizures. - Epilepsy (adjunctive therapy): provides additional seizure control for patients with refractory epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling of tiredness or reduced energy. - Headache: mild to moderate head pain. - Irritability: mood changes or increased agitation.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Mood or behavior changes: depression, suicidal thoughts, or aggression. - Hematologic abnormalities: low blood counts or platelet disorders.

When using Levetiracetam Stragen, consider the following precautions to ensure safe administration.

- Renal function: adjust use in patients with impaired renal clearance. - Pregnancy: safety not established; use only if benefits outweigh risks. - Concomitant CNS depressants: monitor for enhanced sedation. - Psychiatric history: observe for mood alterations. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with several medications; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenobarbital: may decrease efficacy of levetiracetam.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase risk of central nervous system side effects. - Alcohol: can potentiate dizziness and sedation. - Other antiepileptic drugs: monitor seizure control when combined.